Literature DB >> 2896786

Influence of adrenocorticotrophic hormone on the behaviour in the swim test of rats treated chronically with desipramine.

M Volosin1, L Cancela, V Molina.   

Abstract

Chronic desipramine (DMI) administration induced a dose-dependent reduction in the immobility time of the swim test in rats. A combined treatment of ACTH (50 iu kg-1 s.c.) and DMI (5 or 10 mg kg-1 i.p.) for 7 days potentiated the anti-immobility effect of DMI. ACTH 4-10, a fragment peptide with little corticotrophic activity, mimicked ACTH-induced potentiation. No stimulating effect on locomotor activity was observed following seven daily co-administrations of ACTH or ACTH 4-10 and DMI (10 mg kg-1). This behavioural evidence indicates that ACTH potentiation involves a central mechanism and demonstrates a functional interaction between ACTH and DMI at the behavioural level.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896786     DOI: 10.1111/j.2042-7158.1988.tb05160.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  Protective effect of vinpocetine against neurotoxicity of manganese in adult male rats.

Authors:  Rania I Nadeem; Hebatalla I Ahmed; Bahia M El-Sayeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-18       Impact factor: 3.000

2.  Relationship between electrocortical activity and beta-adrenergic receptor function in the rat after chronic desimipramine treatment.

Authors:  F N Krijzer; J Schipper; M T Tulp; P A Koopman
Journal:  J Neural Transm Gen Sect       Date:  1989

3.  Social behavior effects of diphenyl dimethyl bicarboxylate (DDB) in the sensory contact model.

Authors:  Amal M Mahfoz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-28       Impact factor: 3.000

4.  Neuroprotective effects of Wharton's jelly-derived mesenchymal stem cells on motor deficits due to Parkinson's disease.

Authors:  Maryam Sadat Jalali; Alireza Sarkaki; Yaghoub Farbood; Seyed Saeed Azandeh; Esrafil Mansouri; Mohammad Ghasemi Dehcheshmeh; Ghasem Saki
Journal:  Iran J Basic Med Sci       Date:  2021-09       Impact factor: 2.699

5.  Repurposing of Secukinumab as Neuroprotective in Cuprizone-Induced Multiple Sclerosis Experimental Model via Inhibition of Oxidative, Inflammatory, and Neurodegenerative Signaling.

Authors:  Amany El-Shahawy Abdel-Maged; Amany M Gad; Laila Ahmed Rashed; Samar S Azab; Eman A Mohamed; Azza S Awad
Journal:  Mol Neurobiol       Date:  2020-06-08       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.